Literature DB >> 14671092

Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.

Ayumi Kudoh1, Tohru Daikoku, Yutaka Sugaya, Hiroki Isomura, Masatoshi Fujita, Tohru Kiyono, Yukihiro Nishiyama, Tatsuya Tsurumi.   

Abstract

The induction of lytic replication of the Epstein-Barr virus (EBV) completely arrests cell cycle progression, in spite of elevation of S-phase cyclin-dependent kinase (CDK) activity, thereby causing accumulation of hyperphosphorylated forms of retinoblastoma (Rb) protein (A. Kudoh, M. Fujita, T. Kiyono, K. Kuzushima, Y. Sugaya, S. Izuta, Y. Nishiyama, and T. Tsurumi, J. Virol. 77:851-861, 2003). Thus, the EBV lytic program appears to promote specific cell cycle-associated activity involved in the progression from G1 to S phase. We have proposed that this provides a cellular environment that is advantageous for EBV productive infection. Purvalanol A and roscovitine, inhibitors of S-phase CDKs, blocked the viral lytic replication when cells were treated at the early stage of lytic infection, while well-characterized inhibitors of enzymes, such as mitogen-activated protein kinase, phosphatidylinositol 3-kinase, and protein kinase C, known to be involved in BZLF1 gene expression did not. Inhibition of CDK activity resulted in the accumulation of the hypophosphorylated form of Rb protein and inhibition of expression of EBV immediate-early and early proteins. Cycloheximide block-and-release experiments clearly demonstrated that even in the presence of enough amounts of the BZLF1 protein, purvalanol A blocked expression of lytic viral proteins at transcription level. Furthermore, reporter gene experiments confirmed that BZLF1-induced activation of early EBV promoters was impaired in the presence of the CDK inhibitor. We conclude here that the EBV lytic program promotes specific cell cycle-associated activity involved in the progression from G1 to S phase because the S-phase-like cellular environment is essential for the expression of immediate-early and early genes supplying the viral replication proteins and hence for lytic viral replication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14671092      PMCID: PMC303396          DOI: 10.1128/jvi.78.1.104-115.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.

Authors:  C D Darr; A Mauser; S Kenney
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

Authors:  L Meijer; A Borgne; O Mulner; J P Chong; J J Blow; N Inagaki; M Inagaki; J G Delcros; J P Moulinoux
Journal:  Eur J Biochem       Date:  1997-01-15

3.  Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication.

Authors:  Q Zhang; Y Hong; D Dorsky; E Holley-Guthrie; S Zalani; N A Elshiekh; A Kiehl; T Le; S Kenney
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

4.  Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition.

Authors:  A Borgne; L Meijer
Journal:  J Biol Chem       Date:  1996-11-01       Impact factor: 5.157

5.  Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system.

Authors:  T Krude; M Jackman; J Pines; R A Laskey
Journal:  Cell       Date:  1997-01-10       Impact factor: 41.582

6.  Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication.

Authors:  W A Bresnahan; I Boldogh; P Chi; E A Thompson; T Albrecht
Journal:  Virology       Date:  1997-05-12       Impact factor: 3.616

7.  Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1.

Authors:  W A Bresnahan; I Boldogh; E A Thompson; T Albrecht
Journal:  Virology       Date:  1996-10-01       Impact factor: 3.616

8.  Human cytomegalovirus infection inhibits G1/S transition.

Authors:  D Dittmer; E S Mocarski
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

9.  Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S.

Authors:  M Lu; T Shenk
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

10.  Epstein-Barr virus single-stranded DNA-binding protein: purification, characterization, and action on DNA synthesis by the viral DNA polymerase.

Authors:  T Tsurumi; A Kobayashi; K Tamai; H Yamada; T Daikoku; Y Yamashita; Y Nishiyama
Journal:  Virology       Date:  1996-08-15       Impact factor: 3.616

View more
  36 in total

1.  KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2.

Authors:  Mark Cannon; Ethel Cesarman; Chris Boshoff
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Mutation of a single amino acid residue in the basic region of the Epstein-Barr virus (EBV) lytic cycle switch protein Zta (BZLF1) prevents reactivation of EBV from latency.

Authors:  Celine Schelcher; Sarah Valencia; Henri-Jacques Delecluse; Matthew Hicks; Alison J Sinclair
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  The Epstein-Barr virus replication protein BBLF2/3 provides an origin-tethering function through interaction with the zinc finger DNA binding protein ZBRK1 and the KAP-1 corepressor.

Authors:  Gangling Liao; Jian Huang; Elizabeth D Fixman; S Diane Hayward
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Epstein-Barr virus BGLF4 kinase induces premature chromosome condensation through activation of condensin and topoisomerase II.

Authors:  Chung-Pei Lee; Jen-Yang Chen; Jiin-Tarng Wang; Keiji Kimura; Ai Takemoto; Chih-Chung Lu; Mei-Ru Chen
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

5.  Phosphorylation of p27Kip1 by Epstein-Barr virus protein kinase induces its degradation through SCFSkp2 ubiquitin ligase actions during viral lytic replication.

Authors:  Satoko Iwahori; Takayuki Murata; Ayumi Kudoh; Yoshitaka Sato; Sanae Nakayama; Hiroki Isomura; Teru Kanda; Tatsuya Tsurumi
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

6.  Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles.

Authors:  Veronica Sanchez; Deborah H Spector
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance.

Authors:  Myung-Soo Kang; Eun Kyung Lee; Vishal Soni; Timothy A Lewis; Angela N Koehler; Viswanathan Srinivasan; Elliott Kieff
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

8.  S-Like-Phase Cyclin-Dependent Kinases Stabilize the Epstein-Barr Virus BDLF4 Protein To Temporally Control Late Gene Transcription.

Authors:  Yoshitaka Sato; Takahiro Watanabe; Chihiro Suzuki; Yuichi Abe; H M Abdullah Al Masud; Tomoki Inagaki; Masahiro Yoshida; Takeshi Suzuki; Fumi Goshima; Jun Adachi; Takeshi Tomonaga; Takayuki Murata; Hiroshi Kimura
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

9.  The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.

Authors:  Jitka Holcakova; Peter Tomasec; Joachim J Bugert; Eddie Cy Wang; Gavin Wg Wilkinson; Roman Hrstka; Vladimir Krystof; Miroslav Strnad; Borivoj Vojtesek
Journal:  Antivir Chem Chemother       Date:  2010-01-05

10.  Homologous recombinational repair factors are recruited and loaded onto the viral DNA genome in Epstein-Barr virus replication compartments.

Authors:  Ayumi Kudoh; Satoko Iwahori; Yoshitaka Sato; Sanae Nakayama; Hiroki Isomura; Takayuki Murata; Tatsuya Tsurumi
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.